Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Details Textual)

v3.4.0.3
Note 5 - Fair Value Measurements (Details Textual) - Asuragen and Redpath [Member]
$ in Millions
3 Months Ended
Mar. 31, 2016
USD ($)
Business Combination, Contingent Cash Consideration, Deferred Payments $ 4.6
Business Combination, Contingent Cash Consideration, Revenue Based Payments $ 13.9